Lupin Launches Azilsartan Medoxomil Tablets in US; First-to-File
Lupin has launched Azilsartan Medoxomil Tablets in the US after FDA approval. The product is bioequivalent to Edarbi® and is indicated for hypertension treatment. Lupin is the exclusive first-to-file and eligible for 180-day exclusivity. The estimated annual sales of the RLD were USD 53.5 million (₹446.9 crore).
The launch of a generic drug, especially with first-to-file exclusivity, can positively impact revenue and market share, but the overall financial impact will depend on market adoption and competition. The estimated annual sales of the RLD are moderate.
The company has successfully launched a new product in a key market (US) and secured first-to-file exclusivity, indicating a positive development.
Lupin Limited announced the launch of Azilsartan Medoxomil Tablets, 40mg and 80mg, in the United States. This launch follows the U.S. FDA's approval of its Abbreviated New Drug Application.
The product is bioequivalent to Edarbi® by Azurity Pharmaceuticals, Inc. and is indicated for the treatment of hypertension in adults. Lupin has secured exclusive first-to-file status for this product and is eligible for 180-day generic drug exclusivity.
Azilsartan Medoxomil Tablets (RLD Edarbi®) had estimated annual sales of USD 53.5 million (₹446.9 crore) in the U.S. as of IQVIA MAT APRIL 2026.
What to do with a filing like this
Lupin Limited filed this with the NSE as a statutory disclosure, categorised under product launches. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Lupin Limited. Read the original for the full detail.